Share on StockTwits

Isis Pharmaceuticals (NASDAQ:ISIS) Director Joseph Klein III sold 10,313 shares of the company’s stock on the open market in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $48.66, for a total transaction of $501,830.58. Following the completion of the sale, the director now directly owns 2,313 shares in the company, valued at approximately $112,551. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on ISIS shares. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note to investors on Wednesday. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Tuesday. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $39.50.

Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded down 3.49% on Friday, hitting $48.42. The stock had a trading volume of 1,145,267 shares. Isis Pharmaceuticals has a 1-year low of $12.95 and a 1-year high of $51.72. The stock’s 50-day moving average is $42.24 and its 200-day moving average is $34.35. The company’s market cap is $5.620 billion.

Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the previous year, the company posted ($0.37) earnings per share. The company’s revenue for the quarter was up 103.4% on a year-over-year basis. Analysts expect that Isis Pharmaceuticals will post $-0.52 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.